In an increasingly digital world patients seek the same level of convenience and personalization from biopharma companies that they receive from other industries. While momentum for change has been building, conditions are now perfect for an ambitious and fundamental reshaping of outdated processes. It is time for biopharma companies to lead the healthcare industry by becoming more empathetic, impactful, human and truly patient-centric. Yet while they understand the need, implementing the increasingly complex changes necessary for patient centricity place greater demands on the supply chain. New Science, (novel life sciences mechanisms, modalities and platforms addressing significant unmet needs using a unique combination of science and technology) propels this complexity as it is expected to drive 86% of industry revenue growth in the next five years.1
What are the internal and external forces responsible for the pressure and influence to shift towards a patient-centric approach?